The role of erythropoietin in hemorrhagic shock-induced liver and renal injury in rats.
BACKGROUND
The aim of the present study was to evaluate the role of erythropoietin (EPO) in liver and renal injury following hemorrhagic shock (HS) after inhibition of tyrosine kinase activity in rats..


METHODS
Forty-eight Sprague-Dawley rats were assigned to six groups: (I) HS alone; (II) HS followed by retransfusion; (III) EPO and genistein followed by HS; (IV) EPO and genistein followed by HS, followed by retransfusion; (V) HS followed by EPO and genistein; and (VI) HS followed by EPO and genistein, followed by retransfusion. HS was induced for 60 minutes after withdrawal of 30% of the calculated total blood volume of each rat from the left femoral artery. Blood and tissue samples (from the kidney and liver) were obtained 60 minutes after HS in Group I, III, and V; blood and tissue samples were obtained 60 minutes after retransfusion in Group II, IV, and VI. In Group III and IV, EPO was given 60 minutes before HS, and genistein 30 minutes before HS. In Group V and VI, EPO and genistein were given 30 minutes after HS.


RESULTS
Liver and renal injury were significantly attenuated with EPO and genistein administration.


CONCLUSIONS
These results suggest that EPO is effective in attenuating liver and renal injury in HS, even with inhibition of tyrosine kinase activity with genistein.
Algin
Mustafa Cem
MC
Department of General Surgery, Kutahya, Turkey.
Hacioglu
Alper
A
Yaylak
Faik
F
Gulcan
Erim
E
Aydin
Tayfun
T
Hacioglu
Buket Altunkara
BA
Ilhan
Demet
D
Cevik
Arif Alper
AA
Ates
Ersin
E
D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000473:pathology; D018414:CD8-Positive T-Lymphocytes / Q000473:pathology; D004921:Erythropoietin / Q000494:pharmacology*; D019833:Genistein / Q000494:pharmacology; D007376:Interleukin-2 / Q000032:analysis; D007668:Kidney / Q000276:immunology / Q000473:pathology; D007674:Kidney Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008099:Liver / Q000276:immunology / Q000473:pathology; D008107:Liver Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D012771:Shock, Hemorrhagic / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis
D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D019833:Genistein; D011505:Protein-Tyrosine Kinases